Assessing lymphoma treatment response using advanced DNA analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on evaluating the treatment response in patients with aggressive B-cell lymphoma through the analysis of circulating tumor DNA (ctDNA) using phased variant analysis and next-generation sequencing (NGS). The study aims to provide a safer alternative to traditional imaging methods like CT and PET scans, which involve radiation exposure. By analyzing ctDNA, researchers hope to gain insights into the molecular characteristics of the tumor and the patient's clinical status, potentially leading to more accurate early assessments of treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Pathology proven lymphoma

  * Age ≥ 18 years old

Exclusion Criteria:

* none

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Tai-Chung Huang, Ph.D — National Taiwan University Hospital
• Study coordinator: Tai-Chung Huang, Ph.D
• Email: tch01@ntu.edu.tw
• Phone: +886-972-651392

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Carmustine treatment for lymphoma patients

  This study is testing if adding a new drug called VI-0609 to a standard treatment helps lymphoma patients do better after a stem cell transplant.

  Recruiting at 4 sites Phase 2 Vivus LLC · Goodyear, Arizona and 3 other locations · NCT06915246

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Understanding the causes and outcomes of lymphoma in Chinese patients

  This study looks at the clinical and genetic details of lymphoma patients in China to see how these factors affect the disease and its outcomes.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06203652

• Evaluating AZD3470 for relapsed or refractory blood cancers

  This study is testing a new drug called AZD3470 to see if it can help people with hard-to-treat blood cancers feel better and respond to treatment.

  Recruiting at 28 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT06137144

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.